|Bid||17.49 x 1300|
|Ask||17.99 x 34100|
|Day's Range||17.08 - 18.03|
|52 Week Range||13.42 - 32.20|
|Beta (3Y Monthly)||2.91|
|PE Ratio (TTM)||17.38|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.56|
Exelixis (EXEL) and partner Ipsen receive EU approval for the label expansion of Cabometyx (cabozantinib) tablets as a monotherapy for HCC in adults.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 14) Vapotherm, Inc. (NYSE: VAPO )(listed following its IPO) ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Exelixis, Inc. (EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of CABOMETYX in this indication in all 28 member states of the European Union, Norway and Iceland.
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, ...
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Exelixis, Inc. (EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company discovered its three commercially available products, CABOMETYX®(cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib) and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. The company announced that Michael M. Morrissey, Ph.D., the company's President, and Chief Executive Officer, will provide an overview of the company at the Stifel 2018 Healthcare Conference taking place November 13-14 in New York, NY.
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
In the third quarter, Exelixis’s (EXEL) Cabozantinib franchise generated revenues of $162.9 million, reflecting ~69% YoY growth. Exelixis’s Cabometyx generated revenues of $158.3 million in the third quarter, reflecting ~75% YoY growth.
Exelixis reported revenues of $625.2 million in the first nine months of this year compared to $332.4 million in the same period the prior year. In the third quarter, Exelixis generated revenues of $162.9 million from product sales compared to $96.4 million in the third quarter of 2017, reflecting ~69% YoY growth. Exelixis generated $62.5 million in collaboration revenues in the third quarter compared to $56.1 million in the third quarter of 2017.
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / U.S. equities rolled back on Friday, ending a 3-day consecutive gain after confusing headlines about the trade talks with China. President Trump announced ...
Seeing as how several stocks are on the move due to earnings today, let’s take a look at some of the more notable ones, including that of Exelixis Inc. (NASDAQ:EXEL), Symantec Corporation (NASDAQ:SYMC), Acacia Communications Inc. (NASDAQ:ACIA), Universal Display Corporation (NASDAQ:OLED), and Weight Watchers International Inc (NASDAQ:WTW). For those of you interested in potentially partly diversifying your portfolio with hedge […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
On a per-share basis, the Alameda, California-based company said it had profit of 41 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...